Page last updated: 2024-09-05

lapatinib and Stomach Neoplasms

lapatinib has been researched along with Stomach Neoplasms in 60 studies

Research

Studies (60)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (3.33)	29.6817
2010's	51 (85.00)	24.3611
2020's	7 (11.67)	2.80

Authors

Authors	Studies
Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY	1
Ge, L; Gong, H; Hou, L; Jin, X; Leng, G; Li, C; Li, T; Liu, Y; Ma, L; Niu, S; Su, Y; Zhang, H; Zhang, L; Zhao, L	1
Fan, X; Huo, J; Sun, P; Xie, W	1
Hou, R; Li, S; Liu, D; Ma, W; Meng, B; Ren, T; Shi, M; Wang, X; Xu, Z; Zhao, X; Zheng, J	1
Fujita, M; Nakanishi, H; Nakata, S	1
Chen, R; Ding, X; Gao, D; Tong, C; Wang, X; Zhu, L	1
Armstrong, P; Breathnach, O; Carr, A; Cremona, M; Elamin, Y; Farrelly, AM; Fay, J; Grogan, L; Hennessy, BT; Holohan, C; Kay, EW; Madden, S; McAuley, J; Mezynski, MJ; Morgan, C; Morris, PG; Rafee, S; Sheehan, KM; Toomey, S; Workman, J	1
Kang, W; Kwon, JY; Lee, C; Lee, H; Maher, L; Michaud, M; Ning, G; Silva, M; Suh, YS; Zhang, C; Zhu, Q	1
Agarwal, R; Grieb, BC	1
Chang, MS; Choi, Y; Jang, BG; Kim, MA; Kim, Y; Ko, YS; Lee, BL; Lee, JS; Park, J; Park, JW; Pyo, JS	1
Bai, M; Che, X; Liu, Y; Qu, X; Song, N; Wang, X	1
An, J; Bae, JM; Banks, KC; Bass, AJ; Choi, MG; Kang, WK; Kim, K; Kim, NKD; Kim, S; Kim, ST; Kim, SY; Lanman, RB; Lee, H; Lee, J; Lee, JH; Lim, HY; Park, JO; Park, SH; Park, W; Park, YS; Pectasides, E; Sohn, TS; Talasaz, A	1
Chao, J; Klempner, SJ	1
Ding, C; Jiao, XD; Yu, G; Zang, YS	1
Liu, H; Song, Q; Yang, Y; Yu, X; Yu, Y	1
Atasoy, A; Caballero, C; Freire, J; John, JMM; Lang, I; Lutz, MP; Maderer, A; Mauer, ME; Moehler, M; Roth, A; Schad, A; Thomaidis, T; Van Cutsem, E	1
Castillo, J; Cejalvo, JM; Cervantes, A; Fleitas, T; Gambardella, V; Gimeno-Valiente, F; Huerta, M; Martinez-Ciarpaglini, C; Roda, D; Roselló, S; Tarazona, N; Tolosa, P	1
Jiao, S; Ju, Y; Sun, S	1
Choi, J; Hong, YS; Im, HS; Kang, J; Kim, D; Kim, SW; Lee, CH; Lee, DH; Lee, KP; Park, KS; Park, SR; Seo, S; Yoon, S	1
Stirrups, R	1
Hattori, S; Kage, M; Kan, H; Kawahara, A; Kuwano, M; Murakami, Y; Ono, M; Shibata, T; Ureshino, H; Watari, K	1
Boku, N	1
Bang, YJ; Han, SW; Hwang, D; Im, SA; Jeong, EG; Kim, HP; Kim, TY; Lee, MY; Song, SH	1
Furuya, T; Ito, Y; Kodera, Y; Kondo, E; Murakami, H; Nakanishi, H; Oshima, Y; Tanaka, H	1
Sato, Y; Takakura, N; Yashiro, M	1
Fujii, H; Izawa, S; Kiessling, R; Kono, K; Kua, LF; Mimura, K; Mueller, A; Seliger, B; Shiraishi, K; So, J; Yong, WP	1
Gavine, P; Gu, Y; Liu, C; Liu, YJ; Lv, J; Ni, X; Qian, J; Qian, Z; Shen, D; Su, X; Sun, Y; Xu, Y; Yin, X; Zhan, P; Zhang, J; Zhang, T	1
Bang, YJ; Chung, HC; Chung, IJ; Doi, T; Feng, JF; Kobayashi, M; Li, J; Miwa, H; Mukaiyama, A; Ohtsu, A; Omuro, Y; Qin, SK; Satoh, T; Sun, GP; Tsuji, A; Wang, JW; Xu, JM; Xu, RH; Yeh, KH	1
Chang, J; Fang, Q; Geng, R; Ji, D; Li, J; Liu, L; Liu, R; Wang, C; Wang, J; Wu, Z; Xiong, L; Zhang, Z; Zhu, D	1
Bass, AJ; Fox, C; Hong, SW; Hong, YS; Kim, J; Ma, Q; Pectasides, E; Peng, S; Stachler, MD; Thorner, AR; Van Hummelen, P; Wong, GS	1
Ali, SM; Chmielecki, J; Frampton, GM; Lipson, D; Miller, VA; Morosini, D; Palma, N; Palmer, GA; Ross, JS; Stephens, PJ; Wang, K; Yelensky, R	1
Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F	1
Banno, E; Boku, N; De Velasco, MA; Fujita, Y; Mizukami, T; Nakajima, TE; Nishio, K; Sakai, K; Sogabe, S; Terashima, M; Togashi, Y; Tomida, S	1
Ding, P; Guo, Q; Jiang, Z; Li, H; Sun, L; Tian, C; Wang, Z; Yuan, Z; Zhang, L; Zhao, Y	1
Cheow, H; De Silva, N; Fitzgerald, R; Ford, H; Godfrey, E; Hochhauser, D; Jobanputra, M; Lao-Sirieix, P; O'Donovan, M; Paterson, A; Qain, W; Schulz, L; Secrier, M	1
Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM	1
Allemand, DH; Charreau, EH; Cidlowski, JA; Cordo Russo, RI; Cortese, E; De Martino, M; Elizalde, PV; Guzmán, P; Huang, TH; Izzo, F; Mercogliano, MF; Oakley, RH; Pereyra, MG; Proietti, CJ; Rivas, MA; Roa, JC; Schillaci, R; Venturutti, L; Yankilevich, P	1
Briner, C; Gladkov, O; Hsieh, RK; Kaneko, T; Koch, KM; LaBonte, MJ; Lee, WP; Lenz, HJ; Nagarwala, YM; Pishvaian, MJ; Rha, SY; Sakaeva, D; Urba, SG; Wilson, PM; Yang, D; Zhang, W	1
Apicella, M; Capelôa, T; Cargnelutti, M; Casorzo, L; Cassoni, P; Comoglio, PM; Corso, S; De Simone, M; Degiuli, M; Giordano, S; Marsoni, S; Menegon, S; Migliore, C; Sapino, A; Sarotto, I; Sottile, A	1
Ma, L; Qian, J; Shu, Y; Wang, Q; Wang, S; Xu, T; Yang, F; Zhou, J; Zhu, W	1
Afenjar, K; Bang, YJ; Chu, MP; Chua, N; Hecht, JR; Hiller, JP; Hoff, PM; Houe, V; Huang, YJ; Khan-Wasti, S; King, K; Koski, S; Mulder, K; Qin, S; Sawyer, MB; Scarfe, A; Slamon, D; Sobrero, A; Spratlin, J; Wainberg, ZA	1
Chiba, Y; Haratani, K; Hayashi, H; Kawakami, H; Nakagawa, K; Nonagase, Y; Takahama, T; Takeda, M; Takegawa, N; Tamura, T; Tanizaki, J; Tsurutani, J; Ueda, H; Watanabe, S; Yonesaka, K; Yoshida, T	1
Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Ellis, CE; Estrada, MC; Gagnon, RC; Grob, TJ; Hecht, JR; Jeziorski, K; Liang, Z; Ma, Y; Park, JO; Press, MF; Qin, SK; Robinson, DM; Sauter, G; Scherer, SJ; Slamon, DJ; Villalobos, I; Wu, S; Xu, J	1
Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Manegold, PC; Wilson, PM	1
Hede, K	1
Anghel, A; Ayala, R; Desai, AJ; Fejzo, MS; Finn, RS; Hecht, JR; Luo, T; Safran, B; Slamon, DJ; Wainberg, ZA	1
Jørgensen, JT	1
Fukuoka, M; Kiniwa, M; Nakagawa, K; Okamoto, I; Takezawa, K; Tanizaki, J; Tsukioka, S; Uchida, J	1
Cunningham, D; Okines, AF	1
Catalano, G; Ciardiello, F; De Vita, F; Giuliani, F; Orditura, M; Silvestris, N	1
Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T	1
Blanke, CD; Danenberg, KD; Fenoglio-Preiser, CM; Goldman, B; Iqbal, S; Lenz, HJ; Shibata, SI; Zhang, W	1
Dasanu, CA; Kaur, A	1
Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X	1
Aoki, Y; Fujii, T; Hada, K; Ishii, N; Kondoh, O; Mio, T; Miura, T; Nakanishi, Y; Nakano, K; Ono, N; Saitoh, R; Sakata, K; Sato, S; Suda, A; Tachibana, Y; Tsukuda, T; Yamazaki, T	1
Chen, CT; Christensen, JG; Gao, S; Kim, H; Liska, D; Weiser, MR	1
Kołodziejczyk, P; Kulig, J; Kulig, P; Legutko, J	1
Bang, YJ; Elvin, P; Han, SW; Im, SA; Kim, HP; Kim, TY; Min, A; Nam, HJ; Oh, DY; Song, SH; Yoon, YK	1
Fujii, H; Inoue, A; Inoue, M; Izawa, S; Kawaguchi, Y; Kono, K; Maruyama, T; Mimura, K; Shiba, S; Shiraishi, K; Watanabe, M	1

Reviews

6 review(s) available for lapatinib and Stomach Neoplasms

Article	Year
Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis. Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Everolimus; Humans; Lapatinib; Network Meta-Analysis; Nivolumab; Randomized Controlled Trials as Topic; Stomach Neoplasms	2022
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. Current treatment options in oncology, 2021, 08-23, Volume: 22, Issue:10 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Neoplasm; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lapatinib; Oxaliplatin; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab	2021
HER2-positive gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:1 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2014
Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer treatment reviews, 2010, Volume: 36 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2010
Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:16 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Esophageal Neoplasms; Humans; Lapatinib; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2011
Targeted therapy for gastric cancer--current status. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2013, Volume: 19, Issue:1 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drugs, Investigational; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms	2013

Trials

10 trial(s) available for lapatinib and Stomach Neoplasms

Article	Year
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell-Free System; Female; Humans; Lapatinib; Male; Middle Aged; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Young Adult	2018
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071). Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome	2018
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-01, Volume: 32, Issue:19 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Odds Ratio; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome	2014
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome	2015
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. British journal of cancer, 2015, Nov-03, Volume: 113, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Lapatinib; Male; MAP Kinase Signaling System; Middle Aged; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms	2015
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Feb-10, Volume: 34, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult	2016
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. Molecular cancer therapeutics, 2016, Volume: 15, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Disease Progression; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Neoplasm Staging; Polymorphism, Single Nucleotide; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Treatment Outcome	2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA oncology, 2017, Jun-01, Volume: 3, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Interactions; Esophageal Neoplasms; Female; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proton Pump Inhibitors; Quinazolines; Stomach Neoplasms; Treatment Outcome	2017
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Molecular cancer therapeutics, 2017, Volume: 16, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome; Young Adult	2017
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Stomach Neoplasms; Treatment Outcome	2011

Other Studies

44 other study(ies) available for lapatinib and Stomach Neoplasms

Article	Year
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases. Journal of medicinal chemistry, 2012, Mar-22, Volume: 55, Issue:6 Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship	2012
Pyroptosis, apoptosis, and necroptosis molecular subtype derived prognostic signature universal applicable for gastric cancer-A large sample and multicenter retrospective analysis. Computers in biology and medicine, 2022, Volume: 149 Topics: Apoptosis; Axitinib; Cisplatin; Gene Expression Profiling; Humans; Lapatinib; Matrix Metalloproteinase 11; Necroptosis; Organic Anion Transporters; Prognosis; Protein-Lysine 6-Oxidase; Pyroptosis; Stomach Neoplasms; Vinorelbine	2022
Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer. Scientific reports, 2023, Nov-27, Volume: 13, Issue:1 Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; RNA, Long Noncoding; SOXB1 Transcription Factors; Stomach Neoplasms	2023
Efficacy of Afatinib and Lapatinib Against Anticancer research, 2019, Volume: 39, Issue:11 Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Nude; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019
Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer. Journal of molecular graphics & modelling, 2020, Volume: 96 Topics: Humans; Lapatinib; Mutation; Mutation, Missense; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Stomach Neoplasms	2020
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. Journal of translational medicine, 2021, 05-01, Volume: 19, Issue:1 Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2021
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer. BMC cancer, 2021, Aug-16, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Pyridones; Pyrimidines; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2021
FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation. Cancer research and treatment, 2018, Volume: 50, Issue:1 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Forkhead Box Protein O1; Humans; Lapatinib; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Transfection; Up-Regulation	2018
Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer. Cell biology international, 2018, Volume: 42, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms	2018
Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4 Topics: Genomics; Humans; Lapatinib; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome	2018
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report. BMC cancer, 2018, 02-20, Volume: 18, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Capecitabine; Diagnostic Imaging; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Meningeal Carcinomatosis; Multimodal Imaging; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome	2018
miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer. International journal of molecular medicine, 2018, Volume: 42, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; MicroRNAs; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms	2018
NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 03-01, Volume: 25, Issue:5 Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression Profiling; Humans; Lapatinib; Mice; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Ribosomal Protein S6; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2019
Prolonged overall survival in metastatic gastric cancer treated with ipilimumab and lapatinib. Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Humans; Ipilimumab; Lapatinib; Lymphatic Metastasis; Male; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Stomach Neoplasms; Treatment Outcome	2018
HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. BMB reports, 2018, Volume: 51, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Resorcinols; Signal Transduction; Stomach Neoplasms	2018
Lapatinib with chemotherapy for gastro-oesophageal cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:8 Topics: Esophageal Neoplasms; Humans; Lapatinib; Stomach Neoplasms	2019
Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Molecular cancer therapeutics, 2013, Volume: 12, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Y-Box-Binding Protein 1	2013
Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene, 2014, Jun-19, Volume: 33, Issue:25 Topics: beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; G1 Phase; Humans; Lapatinib; Proteoglycans; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Transcription, Genetic; Up-Regulation	2014
Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Mucin-4; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2014
[Chinese expert consensus on the molecular-targeted therapy for HER-2-positive advanced gastric cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Consensus; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2013
Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells. Cancer science, 2013, Volume: 104, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; Lapatinib; Neuregulin-1; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases	2013
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. Journal of immunology (Baltimore, Md. : 1950), 2013, Dec-15, Volume: 191, Issue:12 Topics: Androstadienes; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; HLA-A Antigens; Humans; Lapatinib; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Wortmannin	2013
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Female; Humans; Lapatinib; Male; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Xenograft Model Antitumor Assays	2014
Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Sep-01, Volume: 20, Issue:17 Topics: Antigens, CD; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Middle Aged; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Stomach Neoplasms	2014
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PloS one, 2014, Volume: 9, Issue:10 Topics: Adenocarcinoma; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Amplification; Gene Expression; Gene Silencing; Genes, src; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; Stomach Neoplasms	2014
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. The oncologist, 2015, Volume: 20, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; DNA Copy Number Variations; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2015
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. International journal of oncology, 2015, Volume: 47, Issue:2 Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms	2015
A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells. Apoptosis : an international journal on programmed cell death, 2015, Volume: 20, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; ErbB Receptors; G1 Phase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Resting Phase, Cell Cycle; Signal Transduction; Stomach Neoplasms	2015
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene, 2016, 12-01, Volume: 35, Issue:48 Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclins; Disease Models, Animal; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lapatinib; Male; Mice; MicroRNAs; Models, Biological; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA-Binding Proteins; Stomach Neoplasms; Trastuzumab	2016
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. Oncogene, 2017, 03-02, Volume: 36, Issue:9 Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2017
JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells. Oncotarget, 2016, 11-01, Volume: 7, Issue:44 Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Membrane Transport Proteins; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms	2016
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. Oncotarget, 2016, Dec-20, Volume: 7, Issue:51 Topics: Ado-Trastuzumab Emtansine; Aged; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Male; Maytansine; Middle Aged; Neuregulin-1; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms; Survivin; Trastuzumab	2016
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. International journal of cancer, 2009, Dec-15, Volume: 125, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Chromatography, Liquid; Colonic Neoplasms; Colony-Forming Units Assay; Drug Synergism; ErbB Receptors; Flow Cytometry; Humans; Irinotecan; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
Gastric cancer: trastuzumab trial results spur search for other targets. Journal of the National Cancer Institute, 2009, Oct-07, Volume: 101, Issue:19 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Everolimus; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Receptor, ErbB-2; Sirolimus; Stomach Neoplasms; Survival Analysis; Trastuzumab	2009
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays	2010
Targeted HER2 treatment in advanced gastric cancer. Oncology, 2010, Volume: 78, Issue:1 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab	2010
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Molecular cancer therapeutics, 2010, Volume: 9, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Combinations; Drug Delivery Systems; Drug Synergism; Fluorouracil; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2010
Trastuzumab in gastric cancer. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:11 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Forecasting; Genes, erbB-2; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2010
Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:5 Topics: Abdominal Pain; Adenocarcinoma, Papillary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Immunohistochemistry; Lapatinib; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome	2011
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells. British journal of cancer, 2011, Nov-08, Volume: 105, Issue:10 Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms	2011
Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer science, 2012, Volume: 103, Issue:2 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays	2012
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Molecular cancer therapeutics, 2012, Volume: 11, Issue:3 Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Indoles; Lapatinib; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Stomach Neoplasms; Sulfones	2012
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Molecular cancer therapeutics, 2013, Volume: 12, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Female; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gene Expression; Lapatinib; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Quinazolines; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays	2013
Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2013, Volume: 16, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Tumor Cells, Cultured	2013